Silencing of RASSF3 by DNA Hypermethylation Is Associated with Tumorigenesis in Somatotroph Adenomas

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Peng, Hu ^a   Liu, Huanhai ^a   Zhao, Shuwei ^a   Wu, Jian ^a   Fan, Jingping ^a   Liao, Jianchun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CELL PROTEIN; DNA; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; PROTEIN RASSF3; UNCLASSIFIED DRUG;

ADENOHYPOPHYSIS; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; GENE; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE SILENCING; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PYROSEQUENCING; RASSF3 GENE; RAT; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; AZACITIDINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; MICE; MONOMERIC GTP-BINDING PROTEINS; PROMOTER REGIONS, GENETIC; RATS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

RATTUS;

EID: 84875544282     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059024     Document Type: Article

References (32)

1. Asa SL, Ezzat S, (2009) The pathogenesis of pituitary tumors. Annu Rev Pathol 4: 97-126.
2. Asa SL, Ezzat S, (1998) The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19: 798-827.
3. Michaelis KA, Knox AJ, Xu M, Kiseljak-Vassiliades K, Edwards MG, et al. (2011) Identification of growth arrest and DNA-damage-inducible gene beta (GADD45beta) as a novel tumor suppressor in pituitary gonadotrope tumors. Endocrinology 152: 3603-3613.
4. Asa SL, Ezzat S, (2002) The pathogenesis of pituitary tumours. Nat Rev Cancer 2: 836-849.
5. Melmed S, (2011) Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7: 257-266.
6. Dworakowska D, Korbonits M, Aylwin S, McGregor A, Grossman AB, (2011) The pathology of pituitary adenomas from a clinical perspective. Front Biosci (Schol Ed) 3: 105-116.
7. Faglia G, Spada A, (2001) Genesis of pituitary adenomas: state of the art. J Neurooncol 54: 95-110.
8. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, et al. (1993) CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 8: 1063-1067.
9. Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, et al. (2011) Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene 30: 1390-1401.
10. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE, (2000) Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 60: 1211-1216.
11. Zhu X, Lee K, Asa SL, Ezzat S, (2007) Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am J Pathol 170: 1618-1628.
12. Tai KY, Shiah SG, Shieh YS, Kao YR, Chi CY, et al. (2007) DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression. Oncogene 26: 3989-3997.
13. Qian ZR, Sano T, Yoshimoto K, Yamada S, Ishizuka A, et al. (2005) Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. Lab Invest 85: 464-473.
14. Qian ZR, Sano T, Yoshimoto K, Asa SL, Yamada S, et al. (2007) Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol 20: 1269-1277.
15. Vandeva S, Jaffrain-Rea ML, Daly AF, Tichomirowa M, Zacharieva S, et al. (2010) The genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 24: 461-476.
16. da Costa Prando E, Cavalli LR, Rainho CA, (2011) Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines. Epigenetics 6: 1413-1424.
17. Hesson L, Bieche I, Krex D, Criniere E, Hoang-Xuan K, et al. (2004) Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 23: 2408-2419.
18. Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, et al. (2006) Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 24: 4262-4269.
19. Kawai Y, Sakano S, Suehiro Y, Okada T, Korenaga Y, et al. (2010) Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma. Ann Oncol 21: 1612-1617.
20. Martins AT, Monteiro P, Ramalho-Carvalho J, Costa VL, Dinis-Ribeiro M, et al. (2011) High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. Breast Cancer Res Treat 129: 1-9.
21. Meng W, Huebner A, Shabsigh A, Chakravarti A, Lautenschlaeger T, (2012) Combined RASSF1A and RASSF2A Promoter Methylation Analysis as Diagnostic Biomarker for Bladder Cancer. Mol Biol Int 2012: 701814.
22. Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, et al. (2012) Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma. Clin Cancer Res 18: 808-814.
23. Djos A, Martinsson T, Kogner P, Caren H, (2012) The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma. Mol Cancer 11: 40.
24. Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, et al. (2009) The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer 8: 42.
25. Richter AM, Pfeifer GP, Dammann RH, (2009) The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 1796: 114-128.
26. Jacquemart IC, Springs AE, Chen WY, (2009) Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice. Int J Oncol 34: 517-528.
27. Pelizzola M, Koga Y, Urban AE, Krauthammer M, Weissman S, et al. (2008) MEDME: an experimental and analytical methodology for the estimation of DNA methylation levels based on microarray derived MeDIP-enrichment. Genome Res 18: 1652-1659.
28. Herman JG, Baylin SB, (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054.
29. Tommasi S, Dammann R, Jin SG, Zhang XF, Avruch J, et al. (2002) RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene 21: 2713-2720.
30. Song MS, Song SJ, Kim SY, Oh HJ, Lim DS, (2008) The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. EMBO J 27: 1863-1874.
31. Calvisi DF, Donninger H, Vos MD, Birrer MJ, Gordon L, et al. (2009) NORE1A tumor suppressor candidate modulates p21CIP1 via p53. Cancer Res 69: 4629-4637.
32. Chesnokova V, Zonis S, Zhou C, Ben-Shlomo A, Wawrowsky K, et al. (2011) Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One 6: e17924.